Infinimmune
Latest round
- Series A
Last raised
- Aug 2026
Total raised
- $87M
Investors
- 12
About Infinimmune
Founded in 2022 by Wyatt McDonnell (CEO), Katie Pfeiffer, Mike Gibbons, Lance Hepler, and David Jaffe, and based in California, US, Infinimmune, Inc. operates as a biotechnology research company that develops new methods for antibody drug discovery and development. In August 2026, Infinimmune, Inc. The firm develops antibody-based drugs that address unmet medical needs by screening human samples containing B cells and reading and rewriting the antibody sequences present to create superior drug candidates.
Who invested in Infinimmune
12 investors across 2 rounds
See all investors in Infinimmune
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Infinimmune
Who invested in Infinimmune?
Infinimmune has 12 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Infinimmune raised?
Infinimmune has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Infinimmune last raise money?
Infinimmune's most recent round on record is a Series A, in Aug 2026.
What does Infinimmune do?
Founded in 2022 by Wyatt McDonnell (CEO), Katie Pfeiffer, Mike Gibbons, Lance Hepler, and David Jaffe, and based in California, US, Infinimmune, Inc.
Where is Infinimmune headquartered?
Infinimmune is headquartered in Alameda, US.
Which VCs invest in companies like Infinimmune?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Infinimmune's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Infinimmune? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.